leisure time -WSS

leisure time

author：fashion 2025-09-27 21:27:01 - browse：5145

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Here’s what’s in the FDA plan to include pregnant women in clinical trials

entertainment

WSS

Long Covid research funding gets a major boost from NIH

Medtronic CEO on promising devices for diabetes, hypertension

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Artificial intelligence use in health care faces greater scrutiny in 2024

STAT Boddities: What happens to the brain when we get scared?

Emergency medicine has repudiated 'excited delirium.' Now what?

entertainment

leisure time

leisure time

Hollywood unions extend contract negotiations for actors

Cassava reveals details — and problems — with Alzheimer's study

DIEP, the 'gold standard' of breast reconstruction, is under threat

Paying for Covid pills will soon shift to insurers

Novavax promises a turnaround & Lilly roils the obesity market

Physician subsidies by hospitals soar in wake of No Surprises Act

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: What happened with Sarepta's Duchenne data

Continuity nursing helped my family in our darkest PICU moments

FDA has safety concerns on CRISPR

hotspot

Paying for Covid pills will soon shift to insurers

STAT Boddities: What happens to the brain when we get scared?

Telehealth options flood the market as retailers push virtual care

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Congress considering partial increase for doctor pay in Medicare

Report cites 'urgent' need to recruit more diverse clinical trial participants

knowledge

entertainment

explore

knowledge